Bart van Rhijn
Director of Finance/CFO at NANOBIOTIX
Net worth: - $ as of 30/03/2024
Profile
Bart van Rhijn is currently the Chief Financial Officer at Nanobiotix SA since 2021.
Prior to this, he was the Chief Financial Officer at Servier Pharmaceuticals LLC from 2018 to 2021 and Head-Finance at Galderma International SAS from 2015 to 2018.
He has a graduate degree from the University of Leiden and an MBA from Olin Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NANOBIOTIX SA
-.--% | 23/04/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Bart van Rhijn active positions
Companies | Position | Start |
---|---|---|
NANOBIOTIX | Director of Finance/CFO | 31/05/2021 |
Former positions of Bart van Rhijn
Companies | Position | End |
---|---|---|
Servier Pharmaceuticals LLC
Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee. | Director of Finance/CFO | 30/04/2021 |
Galderma International SAS
Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Corporate Officer/Principal | 31/07/2018 |
Training of Bart van Rhijn
University of Leiden | Graduate Degree |
Olin Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NANOBIOTIX | Health Technology |
Private companies | 2 |
---|---|
Galderma International SAS
Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Health Technology |
Servier Pharmaceuticals LLC
Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee. | Health Technology |
- Stock Market
- Insiders
- Bart van Rhijn